{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7"},{"groupId":"OG001","value":"0"}]}],"title":"Stringent complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3"},{"groupId":"OG001","value":"4.5"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"},{"groupId":"OG001","value":"27.3"}]}],"title":"Very good partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8"},{"groupId":"OG001","value":"28.6"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1"},{"groupId":"OG001","value":"6.5"}]}],"title":"Minimal response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4"},{"groupId":"OG001","value":"21.4"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2"},{"groupId":"OG001","value":"3.9"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5"},{"groupId":"OG001","value":"4.5"}]}],"title":"Not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"BOR:best sequential response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/data cut-off, whichever comes first. Ordering of evaluations from best to worse was: sCR,CR,VGPR,PR, minimal response (MR), stable disease (SD), PD, and not evaluable.CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas,\\<5% plasma cells in bone marrow aspirates. sCR:CR as defined previously plus normal FLC ratio (0.26 to 1.65), absence of clonal cells in bone marrow biopsy. VGPR: serum and urine M-protein detectable by immunofixation,\\>=90% reduction in serum M-protein plus urine M-protein level \\<100mg/24h,\\>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR: \\>=50% reduction of serum M-protein and reduction in 24h urinary M-protein by \\>=90%/\\<200mg/24h. MR:\\>=25% but \\<=49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%. SD: Not meeting criteria for CR,VGPR,PR,MR/PD.","groups":[{"description":"Participants received pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).","id":"OG000","title":"Pd (Pomalidomide + Dexamethasone)"},{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG001","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population.","reportingStatus":"POSTED","timeFrame":"From the date of randomization until disease progression, or death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)","title":"Percentage of Participants With Best Overall Response (BOR) as Per Independent Response Committee","type":"SECONDARY","unitOfMeasure":"percentage of participants"}